

Curriculum Vitae

Personal information Sabine Straus

Work experience

1. Employer: MEB
 - Start date: 072018
 - End date:
 - Position: PRAC chair
 - Activities: chairing the PRAC
 - Country: Netherlands
2. Employer: MEB
 - Start date: 072012
 - End date:
 - Position: staff member
 - Activities: PRAC member
 - Country: Netherlands
3. Employer: MEB
 - Start date: 122005
 - End date: 062012
 - Position: head of PhV
 - Activities:
 - Country: Netherlands
4. Employer: Erasmus MC
 - Start date: 2010
 - End date:
 - Position: associate professor
 - Activities:
 - Country: Netherlands
5. Employer: MEB
 - Start date: 2001
 - End date: 2005
 - Position: senior assessor pharmacovigilance
 - Activities:
 - Country: Netherlands

Education and training

1. Subject: university Utrecht
 - Start date: 091978
 - End date: 1985
 - Qualification: MD
 - Organisation:
 - Country: Netherlands
2. Subject: erasmus university
 - Start date: 2002
 - End date: 2003
 - Qualification: MSc in Epidemiology
 - Organisation:
 - Country: Netherlands
3. Subject: erasmus university
 - Start date: 2001
 - End date: 2005
 - Qualification: PhD
 - Organisation:
 - Country: Netherlands

Additional information

Publications

Priya Bahri, Daniel R. Morales, Adrien Inoubli, Jean_Michel Dogné, Sabine M. J. M. Straus Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET). Drug Safety; November 2020

Aniello Santoro, Irina Caplanusi, Fergus Sweeney, Benedicte Cappelli, Lorraine Nolan, Sabine Straus, Peter Arlett Navigating stormy waters: 10 years of operation of the European Union Regulatory Network Incident Management Plan for Medicines for Human Use Pharmacoevidentiol Drug Saf. 2020;29:1343–1352. Joanne Potts, Georgy Genov, Andrej Segec, June Raine, Sabine Straus, Peter Arlett Improving the Safety of Medicines in the European Union: From Signals to Action Clin Pharmacol Ther. 2020 Mar; 107(3): 521–529. Peter Arlett, Sabine Straus, Guido Rasi Pharmacovigilance 2030: Invited Commentary for the January 2020 "Futures" Edition of Clinical Pharmacology and Therapeutics Clin Pharmacol Ther. 2020 Jan; 107(1): 89–91. Published online 2019 Nov 22. Christina E. Hoeve, Reynold D. C. Francisca, Inge Zomerdijs, Miriam C. J. M. Sturkenboom, Sabine M. J. M. Straus Description of the Risk Management of Medication Errors for Centrally Authorised Products in the European Union Drug Saf. 2020; 43(1): 45–55. Kartini Gadroen, Jeanet M Kemmeren, Patricia CJ Bruijning_Verhagen, Sabine MJM Straus, Daniel Weibel, Hester E de Melker, Miriam CJM Sturkenboom Baseline incidence of intussusception in early childhood before rotavirus vaccine introduction, the Netherlands, January 2008 to December 2012 Euro Surveill. 2017 Jun 22; 22(25): 30556. doi: 10.2807/1560_7917.ES.2017.22.25.30556 Hoeve CE, van Haren A, Sturkenboom MCJM, Straus SMJM. Spontaneous reports of vaccination errors in the European regulatory database EudraVigilance: A descriptive

study Vaccine. 2018 Dec 18;36(52):7956_7964. doi: 10.1016/j.vaccine.2018.11.003. Epub 2018 Nov 8. Francisca RDC, Zomerdijs IM, Sturkenboom MCJM, Straus SMJM. Measuring the impact of the 2012 European pharmacovigilance legislation on additional risk minimization measures. Expert Opin Drug Saf. 2018 Oct;17(10):975_982. Vatzaki E, Straus S, Dagne JM, Garcia Burgos J, Girard T, Martelletti P. Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation J Headache Pain. 2018 Aug 14;19(1):68. doi: 10.1186/s10194_018_0898_3. Kälviäinen R, Straus S, Dagne JM, Bakchine S, Haas M Reducing valproate use in women with epilepsy. Lancet Neurol. 2018 Jul;17(7):580_581. doi: 10.1016/S1474_4422(18)30172_8 Mazzaglia G, Straus SMJ, Arlett P, da Silva D, Janssen H, Raine J, Alteri E. Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs. Drug Saf. 2018 Feb;41(2):191_202 Pacurariu AC, Coloma PM, Gross Martirosyan L, Sturkenboom MC, Straus SM. Decision making in drug safety: a literature review of criteria used to prioritize newly detected safety issues. Pharmacoepidemiol Drug Saf. 2017 Mar;26(3):327_334 Gadroen K, Kemmeren JM, Bruijning Verhagen PC, Straus SM, Weibel D, de Melker HE, Sturkenboom MC. Baseline incidence of intussusception in early childhood before rotavirus vaccine introduction, the Netherlands, January 2008 to December 2012. Euro Surveill. 2017 Jun 22;22(25). Gadroen K, Straus SM, Pacurariu A, Weibel D, Kurz X, Sturkenboom MC. Patterns of spontaneous reports on narcolepsy following administration of pandemic influenza vaccine; a case series of individual case safety reports in Eudravigilance. Vaccine. 2016 Sep 22;34(41):4892_7 de Bie S, Kaguelidou F, Verhamme KM, de Ridder M, Picelli G, Straus SM, Giallardo C, Stricker BH, Bielicki J, Sharland M, Sturkenboom MC; ARPEC study Using Prescription Patterns in Primary Care to Derive New Quality Indicators for Childhood Community Antibiotic Prescribing. Pediatr Infect Dis J. 2016 Dec;35(12):1317_1323 Vermeer NS, Ebberts HC, Straus SM, Leufkens HG, Egberts TC, de Bruin ML. The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study. Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):297_306. Pacurariu AC, Straus SM, Trifiro G, Schuemie MJ, Gini R, Herings R, Mazzaglia G, Picelli G, Ghirardi A, Pedersen L, Stricker BH, van der Lei J, Sturkenboom MC, Coloma PM. Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection. Drug Saf. 2015 Dec;38(12):1201_10. Vermeer NS, Straus SM, Mantel Teeuwisse AK, Hidalgo Simon A, Egberts AC, Leufkens HG, De Bruin ML. Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab. Clin Pharmacol Ther. 2015 Nov;98(5):542_50 Segec A, Keller Stanislowski B, Vermeer NS, Macchiarulo C, Straus SM, Hidalgo Simon A, De Bruin ML. Strategy in Regulatory Decision Making for Management of Progressive Multifocal Leukoencephalopathy. Clin Pharmacol Ther. 2015 Nov;98(5):502_5. de Bie S, Ferrajolo C, Straus SM, Verhamme KM, Bonhoeffer J, Wong IC, Sturkenboom MC; GRIP network. Pediatric Drug Safety Surveillance in FDA AERS: A Description of Adverse Events from GRIP Project. PLoS One. 2015 Jun 19;10(6): de Bie S, Coloma PM, Ferrajolo C, Verhamme KM, Trifiro G, Schuemie MJ, Straus SM, Gini R, Herings R, Mazzaglia G, Picelli G, Ghirardi A, Pedersen L, Stricker BH, van der Lei J, Sturkenboom MC; EU ADR consortium. The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study. Br J Clin Pharmacol. 2015 Aug;80(2):304_14 Patadia VK, Schuemie MJ, Coloma P, Herings R, van der Lei J, Straus S, Sturkenboom M, Trifiro G. Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection. Int J Clin Pharm. 2015 Feb;37(1):94_104. de Bie S, Coloma PM, Ferrajolo C, Verhamme KM, Trifiro G, Schuemie MJ, Straus SM, Gini R, Herings R, Mazzaglia G, Picelli G, Ghirardi A, Pedersen L, Stricker BH, van der Lei J, Sturkenboom MC; on behalf of the EU ADR consortium. The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study. Br J Clin Pharmacol. 2015 Feb 16. [Epub ahead of print] Niels S Vermeer, Irina Spierings, Aukje K Mantel Teeuwisse, Sabine MJM Straus, Thijs J Giezen, Hubert GM Leufkens, Toine CG Egberts, and Marie L De Bruin Traceability of biologicals: present challenges in pharmacovigilance Expert Opin. Drug Saf 2014; 14(1) Vermeer NS, Duijnhoven RG, Straus SM, Mantel Teeuwisse AK, Arlett PR, Egberts AC, Leufkens HG, De Bruin ML. Risk Management Plans as a Tool for Proactive Pharmacovigilance: A Cohort Study of Newly Approved Drugs in Europe. Clin Pharmacol Ther 2014 e publication Sep 15. Duijnhoven RG, Straus SM, Souverein PC, de Boer A, Bosch JL, Hoes AW, De Bruin ML. Long term use of 5α-reductase inhibitors and the risk of male breast cancer. Cancer Causes Control 2014 Nov;25(11):1577_82. van Blijderveen JC, Straus SM, Rodenburg EM, Zietse R, Stricker BH, Sturkenboom MC, Verhamme KM. Risk of hyponatremia with diuretics: chlorthalidone versus hydrochlorothiazide. Am J Med. 2014 Aug;127(8):763_71. van Blijderveen JC, Straus SM, de Ridder MA, Stricker BH, Sturkenboom MC, Verhamme KM. Adherence to renal function monitoring guidelines in patients starting antihypertensive therapy with diuretics and RAAS inhibitors: a retrospective cohort study. Drug Saf. 2014;37(5):369_77. van Blijderveen JC, Straus SM, Zietse R, Stricker BH, Sturkenboom MC, Verhamme KM. A population-based study on the prevalence and incidence of chronic kidney disease in the Netherlands. Int Urol Nephrol. 2014;46(3):583_92. Peter G. M. Mol, Arna H. Arnardottir, Domenico Motola, Patrick J. Vrijlandt, Ruben G. Duijnhoven, Flora M. Haaijer Ruskamp, Pieter A. de Graeff, Petra Denig, Sabine M. J. M. Straus Post-Approval Safety Issues with Innovative Drugs: A European Cohort Study. Drug Saf. 2013 ;36(11):1105_15 Inge M. Zomerdijs, Gianluca Trifiro, Fakhredin A. Sayed Tabatabaei, Miriam C. J. M. Sturkenboom and Sabine M. J. M. Straus Measuring the effect of risk minimization measures – can existing healthcare databases be used? Pharmacoepidemiol Drug Saf. 2013;22(10):1046_53. Niels S. Vermeer, Sabine M. J. M. Straus, Aukje K. Mantel Teeuwisse, Francois Domergue, Toine C. G. Egberts, Hubert G. M. Leufkens, Marie L. De Bruin Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A Cross-Sectional Study in the FDA Adverse Event Reporting System (FAERS) and Eudravigilance Databases Drug Safety published online June 2013 Van Blijderveen JC, Verhamme KM, Zietse R, Visser LE, Romio SA, Buhre PN, Sturkenboom MC, Hofman A, Straus SM, Stricker BH Overanticoagulation is associated with renal function decline. J Nephrol. 2013 Jul 12;26(4):691_8 Duijnhoven RG, Straus SM, Raine JM, de Boer A, Hoes AW, De Bruin ML. Number of patients studied prior to approval of new medicines: a database study PLoS Med. 2013 Mar;10(3):e1001407 Reber KC, Piening S, Wieringa JE, Straus SM, Raine JM, de Graeff PA, Haaijer Ruskamp FM, Mol PG When direct health care professional communications have an impact on inappropriate and unsafe use of medicines Clin Pharmacol Ther. 2013 Apr;93(4):360_5. Crijns I, Mantel Teeuwisse A, Bloembergen R, Pinas E, Straus S, de Jong van den Berg L. Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: a descriptive study. Expert Opin Drug Saf. 2013 Jan;12(1):29_38 Piening S, Haaijer Ruskamp FM, de Graeff PA, Straus SM, Mol PG. Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands. Drug Saf. 2012;35(11):1061_72. Willemen MJ, Mantel Teeuwisse AK, Buggy Y, Layton D, Straus SM, Leufkens HG, Egberts TC. Reasons for and Time to Discontinuation of Rimonabant Therapy: A Modified Prescription Event Monitoring Study. Drug Saf. 2012 Oct 15. Giezen TJ, Mantel Teeuwisse AK, ten Berg MJ, Straus SM, Leufkens HG, van Solinge WW, Egberts TC. Rituximab-induced thrombocytopenia: a cohort study. Eur J Haematol. 2012; 89(3):256_66. de Bie S, Verhamme KM, Straus SM, Stricker BH, Sturkenboom MC Vaccine-based subgroup analysis in VigilBase: effect on sensitivity in paediatric signal detection. Drug Saf. 2012;35(4):335_46. Rijkje Ruiters, Loes E. Visser, Myrthe P.P. van Herk Sukel, Petronella H. Geelhoed Duijvestijn, Sandra de Bie, Sabine M.J.M. Straus, Peter G.M. Mol, Silvana A. Romio, Ron M.C. Herings and Bruno H.C. Stricker Prescribing of Rosiglitazone and Pioglitazone Following Safety Signals Analysis of Trends in Dispensing Patterns in the Netherlands from 1998 to 2008 Drug Safety 2012;35(6) 471_480 Zomerdijs IM, Sayed Tabatabaei FA, Trifiro G, Blackburn SC, Sturkenboom MC, Straus SM. Risk Minimization Activities of Centrally Authorized Products in the EU: A Descriptive Study. Drug Safety 2012; 35 (4): 299_314 Piening S, Haaijer Ruskamp FM, de Vries JT, van der Elst ME, de Graeff PA, Straus SM, Mol PG. Impact of safety-related regulatory action on clinical practice: a systematic review. Drug Saf. 2012;35(5):373_85. Piening S, Reber KC, Wieringa JE, Straus SM, de Graeff PA, Haaijer Ruskamp FM, Mol PG. Impact of safety-related regulatory action on drug use in ambulatory care in the Netherlands. Clin Pharmacol Ther. 2012;91(5):838_45. Crijns HJ, van Rein N, Gispens de Wied CC, Straus SM, de Jong van den Berg LT. Prescriptive contraceptive use among isotretinoin users in the Netherlands in comparison with non-users: a drug utilisation study. Pharmacoepidemiol Drug Saf. 2012 Crijns, Ineke; Straus, Sabine; Luteijn, Michiel; Gispens de Wied, Christine; Raine, June; de Jong van den Berg, Lolkje Implementation of the Harmonized EU Isotretinoin Pregnancy Prevention Programme: A Questionnaire Survey among European Regulatory Agencies Drug Safety 2012;35(1):27_32 Ruiters R, Visser LE, van Herk Sukel MP, Coebergh JW, Haak HR, Geelhoed Duijvestijn PH, Straus SM, Herings RM, Stricker BH. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care. 2012 Jan;35(1):119_24 Arna H. Arnardottir, Flora M. Haaijer Ruskamp, Sabine M.J. Straus, Pieter A. de Graeff, Peter G.M. Mol Effect of Safety Issues with HIV Drugs on the Approval Process of Other Drugs in the Same Class: An Analysis of European Public Assessment Reports. Drug Safety 2011;34(11):1101_1114 Ruiters R, Visser LE, van Herk Sukel MP, Coebergh JW,

Haak HR, Geelhoed_Duijvestijn PH, Straus SM, Herings RM, Stricker BH. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population_based follow_up study. *Diabetologia*. 2012 Jan;55(1):51_62. Epub 2011 14Crijns HJ, Jentink J, Garne E, Gispen_de Wied CC, Straus SM, de Jong_van den Berg LT; for the EUROCAT Working Group. The Distribution of Congenital Anomalies Within the VACTERL Association Among Tumor Necrosis Factor Antagonist_exposed Pregnancies Is Similar to the General Population. *J Rheumatol*. 2011;38(9):1871_1874 Härmark L, van Puijnenbroek E, Straus S, van Grootheest K. Intensive monitoring of pregabalin: results from an observational, Web_based, prospective cohort study in the Netherlands using patients as a source of information. *Drug Saf*. 2011;34(3):221_31 Teichert M, Visser LE, Uitterlinden AG, Hofman A, Buhre PJ, Straus S, De Smet PA, Stricker BH. Selective serotonin reuptake inhibiting antidepressants and the risk of overanticoagulation during acenocoumarol maintenance treatment. *Br J Clin Pharmacol*. 2011 May 4 Arnardottir AH, Haaïjer_Ruskamp FM, Straus SM, Eichler HG, de Graeff PA, Mol PG. Additional safety risk to exceptionally approved drugs in Europe? *Br J Clin Pharmacol*. 2011;72(3):490_9 Willemen MJ, Mantel_Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC Leufkens HG. Use of dipeptidyl peptidase_4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization Vigibase. *Diabetes Care*. 2011;34(2):369_74 H.J.M.J. Crijns, S.M. Straus, C.h. Gispen_de Wied, L.T.W De Jong_van den Berg : Compliance with Pregnancy Prevention Programs of isotretinoin in Europe: a systematic review *British Journal of Dermatology* 2011;164(2):238_44 Teichert M, van Noord C, Uitterlinden AG, Hofman A, Buhre PN, De Smet PA, Straus S, Stricker BH, Visser LE. Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment. *Br J Haematol*. 2011 May;153(3):379_85 van Noord C, Sturkenboom MC, Straus SM, Witteman JC, Stricker BH. Non_cardiovascular drugs that inhibit hERG_encoded potassium channels and risk of sudden cardiac death. *Heart*. 2011;97(3):215_20 Thijs J. Giezen, Aukje K. Mantel_Teeuwisse, Ronald H.B. Meyboom, Sabine M.J.M. Straus, Hubert G.M. Leufkens, and Toine C.G. Egberts Mapping the Safety Profile of Biologicals. A Disproportionality Analysis Using the WHO Adverse Drug Reaction Database, Vigibase *Drug Saf*;2010;3:865_878 Peter G.M. Mol, Sabine M.J.M. Straus, Sigrid Piening, Jonie T.N. de Vries, Pieter A. de Graeff and Flora M. Haaïjer_Ruskamp A Decade of Safety_related Regulatory Action in the Netherlands. A Retrospective Analysis of Direct Healthcare Professional Communications issued by Pharmaceutical Companies in Collaboration with the Dutch Medicines Evaluation Board and European Medicines Agency (EMA) from 1999 to 2009. *Drug Saf* 2010;33:463_74 Martina Teichert, Loes E Visser, Mark Dufour, Eline Rodenburg, Sabine MJM Straus, Peter AGM De Smet , Bruno HCh Stricker Isotretinoin use and compliance with the Dutch pregnancy prevention program: a retrospective cohort study in Dutch females of reproductive age with pharmacy dispensing data. *Drug Saf*;2010;33:315_26 van Noord C, Sturkenboom M, Straus S, Hofman A, Kors J, Witteman J, Stricker B Serum glucose and insulin are associated with Qtcand RR intervals in non diabetic elderly. *Eur J Endocrinol* 2010;162:241_248 van Noord C, Dörr M, Sturkenboom MC, Straus SM, Reffellmann T, Felix SB, Hofman A, Kors JA, Haring R, de Jong FH, Nauck M, Uitterlinden AG, Wallaschofski H, Witteman JC, Völzke H, Stricker BH. The association of serum testosterone levels and ventricular repolarization *Eur J Epidemiol*. 2010;25(1):21_8 Thijs J. Giezen, Aukje K. Mantel_Teeuwisse, Sabine M.J.M. Straus, Antoine C.G. Egberts, Stella Blackburn, Ingemar Persson, Hubert G.M. Leufkens. Evaluation of Post_Authorisation Safety Studies in the first cohort of EU Risk Management Plans at time of regulatory approval: Where are we?" *Drug Saf* 2009; 32 (12): 1175_1187 Charlotte van Noord, MD, Miriam C.J.M. Sturkenboom, PharmD, PhD, Sabine M.J.M. Straus MD, PhD, Albert Hofman, MD, PhD, Jacqueline C.M. Witteman, PhD, Bruno H. Ch. Stricker, MMed, PhD Population_based studies of antithyroid drugs and sudden cardiac death *Br J Clin Pharmacol* 2009;68 (3): 447-454 Thijs J. Giezen, Sabine M.J.M. Straus, Aukje K. Mantel_Teeuwisse Pharmacovigilance of biosimilars from a regulatory point of view: Is there a need for a specific approach? *International Journal of Risk & Safety in Medicine* 2009 (21) 53-58 Willemen MJ, Mantel_Teeuwisse AK, Straus SM, Leufkens HG, Egberts AC, Sturkenboom MC. Cardiovascular and psychiatric risk profile and patterns of use in patients starting anti_obesity drugs. *Pharmacoepidemiol Drug Saf*. 2009;18(7):631_8 Charlotte van Noord, Albert_Jan L.H.J. Aarnoudse, Mark Eijgelsheim, Miriam C.J.M. Sturkenboom, Sabine M.J.M. Straus, Albert Hofman, Jan A. Kors, Christopher Newton_Cheh, Jacqueline C.M. Witteman, Bruno H.Ch. Stricker, Calcium channel blockers, NOS1AP and QTc prolongation. *Pharmacogenetics and Genomics*, 2009;19(4):260_6 van Noord C, Straus SM, Sturkenboom MC, Hofman A, Aarnoudse AJ, Bagnardi V, Kors JA, Newton_Cheh C, Witteman JC, Stricker BH. Psychotropic drugs associated with corrected QT interval prolongation. *J Clin Psychopharmacol*. 2009 ; 29(1):9_15 van Noord C, van der Deure WM, Sturkenboom MC, Straus SM, Hofman A, Visser TJ, Kors JA, Witteman JC, Stricker BH. High free thyroxine levels are associated with QTc prolongation in males. *J Endocrinol*. 2008;198(1):253_60. Willemen MJ, Mantel_Teeuwisse AK, Straus SM, Leufkens HG, Egberts AC Psychiatric and cardiovascular comorbidities in patients with diabetes mellitusstarting antiobesity drugs. *Obesity* 2008;16(10):2331_5. Giezen T, Mantel_Teeuwisse A, Straus S, Schellekens H, Leufkens H, Egberts A Safety_related regulatory actions for biologicals approved in the US and Europe since 1995. *JAMA* 2008;300(16):1887_1896. Giezen T, PharmD; Mantel_Teeuwisse A, PhD, Leufkens H, PhD, Egberts A, PhD, Straus S, MD PhD. Risk management of biopharmaceuticals: A regulatory perspective. *European Journal of Hospital Pharmacy Practice*. 2007;6: 72_74 van der Sande MA, van Asten L, Straus SM, Schim van der Loeff MF, Wallinga J, Conyn_van Spaendonck MA Sudden deaths following influenza vaccination: Can this be expected? *Vaccine* 2008; 26(3):379_82. Aarnoudse AJ, Newton_Cheh C, de Bakker PI, Straus SM, Kors JA, Hofman A, Uitterlinden AG, Witteman JC, Stricker BH Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam Study. *Circulation*. 2007;116(1):10_6 Sabine M.J.M. Straus, Jan A. Kors, Marie L. De Bruin, Cornelis S. van der Hooft, Albert Hofman, Jan Heeringa, Jaap W. Deckers, J Herre Kingma, Miriam CJM Sturkenboom, Bruno HCh Stricker, Jacqueline C.M. Witteman. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. *J Am Coll Cardiol*. 2006;47(2):362_7. Dieleman JP, van Wyk JT, van Wijk MA, van Herpen G, Straus SM, Dunselman H, Sturkenboom MC. Differences between statins on clinical endpoints: a population_based cohort study. *Curr Med Res Opin*. 2005; 9:1461_8 Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, Witteman JC, Stricker BH. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. *Eur Heart J*. 2004 (18):1614_9. Straus SMJM, Bleumink GS, Dieleman JP, van der Lei J, 't Jong GW, Kingma JH, Sturkenboom MC. Antipsychotics and the risk of sudden cardiac death. *Arch Intern Med*. 2004;164(12):1293_7. Straus SMJM, Bleumink GS, Dieleman JP, Lei van der J, Stricker BHCh, Sturkenboom MCJM. Incidence of sudden cardiac death in the general population. *J Clin Epidemiol*. 2004;57(1):98_102. Nederlandse publicaties C. van Noord, .S M.J.M. Straus, R van Mechelen, J.M. Akkerhuis,M. C.J.M. Sturkenboom, B. H. Ch. Stricker. QTc verlenging bij electrocardiografie en medicatie in de praktijk. *Modern Medicin* 2009;33(6):193_6 Swaan CM, van der Sande MA, Speelman P, Conyn_van Spaendonck MA, Straus SM, Coutinho RA.Biiwerkingen van influenza vaccinatie [Adverse events following influenza vaccination: reaction to specific reports and the necessity of a central registration system] *Ned Tijdschr Geneesk*. 2007;151(39):2166_9.. Straus S.M.J.M, Lekkerkerker J.F.F. Kennis zonder bijwerkingen Medisch Contact 2004;37:144_1446 Voordouw ACG, Straus SMJM. Kunnen er weer griepachtige verschijnselen ontstaan na een 2e vaccinatie tegen hepatitis B? [What is known about the recurrence of flu_like symptoms following a second vaccination against hepatitis B?] *Vademecum*, 2001, nr.22 van Grootheest AC, Straus SMJM, Heeringa M. Bijwerkingen van Sildenafil, 2 jaar praktijkervaring [Side effects of sildenafil: findings from two years practical experience] *Ned Tijdschr Geneesk*. 2001 ;145(11):526_9. Straus S, Nab HW, Meiners AP, Broekmans AW Post_marketing surveillance: wetenschappelijk onderzoek of promotie van geneesmiddelen. *Huisarts en wetenschap* 1999 ; 42: 505_08 SMJM Nierop_Straus Acupunctuur en verslaving. *Acupunctur* 1989;13:14_24 WMA Verhoeven en S. Straus Neuropeptiden en depressie *Tijdschrift voor psychiatrie* 1986 (9):622_32

Projects

involvement in supervision of academic research/PhD research , covering (additional) risk minimisation measures, medication errors, risk communication, methodology in signal detection, renal ADR and biologicals. advisory role in SAFEGUARD (The European project SAFEGUARD aims to assess and further quantify and understand the cardio/cerebrovascular and pancreatic safety of blood glucose lowering agents, in particular the thiazolidinedones (TZDs) and the novel incretin_based drugs and amylin analogues in Type 2 Diabetes Mellitus (T2DM) patients) ARITMO (the European project ARITMO aims to analyse the arrhythmic potential of drugs in the following classes of study drugs (> 250 compounds): antipsychotics, anti_infectives (antibacterials, antimycotics and antivirals) and H1_antihistamines, globally and in specific subgroups (age, co_morbidity, genetically).

Memberships

ISPE

Other Relevant Information